Hydrogen-Rich Water Potentiates Cannabinoid- and Gabapentinoid-Induced Analgesia in Neuropathic Pain.
Nuria Andrea Tort, Sylmara Esther Negrini-Ferrari, Olga Pol · International journal of molecular sciences · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In male C57BL/6 mice, each treatment reduced pain-like behaviors in a dose-dependent manner, while co-administration of HRW with JWH-133 or pregabalin produced greater analgesic effects. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in male C57BL/6 mice. Each treatment reduced pain-like behaviors in a dose-dependent manner, while co-administration of HRW with JWH-133 or pregabalin produced greater analgesic effects.
What the Researchers Studied
The researchers studied male C57BL/6 mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 0.3 mM H₂ (≈0.605 mg/L); Source-reported hydrogen exposure: 10 mL hydrogen-rich water per reported dose; approximately 0.01 mg H₂ per reported serving. Each treatment reduced pain-like behaviors in a dose-dependent manner, while co-administration of HRW with JWH-133 or pregabalin produced greater analgesic effects. The authors concluded that HRW as a promising adjuvant to cannabinoid and gabapentinoid therapies, potentially improving efficacy and reducing high-dose drug-related adverse effects. Molecular hydrogen, recognized for its antioxidant and anti-inflammatory actions, may act as a valuable adjunct to conventional analgesics. This study examined whether hydrogen-rich water (HRW) could potentiate the analgesic effects of JWH-133, a selective cannabinoid receptor type 2 agonist, and pregabalin, a gabapentinoid, in male C57BL/6 mice with NP induced by chronic constriction of the sciatic nerve.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was male C57BL/6 mice. The reported sample size was 4. The study used a preclinical animal experiment. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 0.3 mM H₂ (≈0.605 mg/L). The source-reported hydrogen exposure was 10 mL hydrogen-rich water per reported dose; approximately 0.01 mg H₂ per reported serving.
Limitations and Safety
Safety information: Given the favorable safety profile of H₂ compared with the well-known adverse effects of morphine, its co-administration with JWH-133 may represent a safer and more effective therapeutic strategy for the management of NP.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.